| 1 |
33931001 | Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment. | 2021 Jun |
1 |
| 2 |
31556777 | Effects of cigarette smoking on older chinese men treated with clopidogrel monotherapy or aspirin monotherapy: a prospective study. | 2020 Jul 3 |
1 |
| 3 |
30911318 | A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease. | 2019 |
1 |
| 4 |
30422888 | Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. | 2018 Dec |
1 |
| 5 |
26367336 | Does "smoker's paradox" exist in clopidogrel-treated Turkish patients with acute coronary syndrome. | 2016 |
1 |
| 6 |
24518848 | [Clopidogrel cannot yet be exclusively for smokers]. | 2014 |
1 |
| 7 |
23591705 | Cigarette smoking and clopidogrel interaction. | 2013 May |
1 |
| 8 |
22440495 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. | 2012 Mar |
1 |
| 9 |
21148426 | Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status. | 2011 Mar |
3 |
| 10 |
21884870 | Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. | 2011 Sep |
1 |
| 11 |
25083217 | Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. | 2011 Dec |
1 |
| 12 |
19636246 | Clopidogrel pharmacogenetics and its clinical implications. | 2010 May-Jun |
1 |
| 13 |
20942779 | Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. | 2010 Oct |
1 |
| 14 |
21095272 | Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. | 2010 Nov |
1 |
| 15 |
19358940 | Interaction between cigarette smoking and clinical benefit of clopidogrel. | 2009 Apr 14 |
2 |
| 16 |
19704027 | A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. | 2009 Nov |
1 |
| 17 |
18474675 | Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. | 2008 Aug |
1 |
| 18 |
18687246 | The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. | 2008 Aug 12 |
2 |
| 19 |
17361128 | Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. | 2007 May |
1 |
| 20 |
16772608 | Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. | 2006 Oct 1 |
1 |